{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:26:23Z","timestamp":1790670383497,"version":"4.1.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2020JJ4795"],"award-info":[{"award-number":["2020JJ4795"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Major depressive disorder (MDD) is a highly prevalent and burdensome condition. This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine in treating MDD based on real-world data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of 8 electronic databases was performed from inception until October 2022 to identify real-world studies, excluding randomized controlled trials. We conducted subgroup, meta-regression, sensitivity analyses, publication bias, and quality assessments using the random-effects model. The effects were summarized by rates or standardized mean difference (SMD) with 95% confidence interval (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 870 records identified, 11 studies (3139 participants) and 10 case reports or series were eligible for inclusion. Vortioxetine significantly relieved depression symptoms as assessed by both patients (SMD = 2.25, 95% CI = 1.60\u22122.89) and physicians (SMD = 3.73, 95% CI = 2.78\u22124.69). Cognitive function (SMD =1.86, 95% CI = 1.11\u22122.62) and functional disability (SMD =1.71, 95% CI = 1.14\u22122.29) were similarly markedly improved. Subgroup and meta-regression analyses showed that geographic location and medication regimen (whether combined with other antidepressants) were crucial factors influencing effectiveness (in terms of depression severity and cognitive function), potentially contributing to significant heterogeneity. The estimated response and remission rates were 66.4% (95% CI = 51.2%\u221281.5%) and 58.0% (95% CI = 48.9%\u221267.1%), respectively. Vortioxetine was well tolerated, with a pooled dropout rate of 3.5% (95% CI = 1.8%\u22125.8%), and the most common adverse event was nausea, with an estimated rate of 8.9% (95% CI = 3.8%\u221215.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>The study has some limitations, including significant heterogeneity and limited evidence for some outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Vortioxetine is effective, well tolerated, and safe for treating MDD in clinical practice, with significant improvements observed in depressive severity, cognitive function, and functioning. Future studies should directly compare vortioxetine with other antidepressants in real-world settings to further evaluate its clinical utility.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ijnp\/pyad018","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T01:10:23Z","timestamp":1682644223000},"page":"373-384","source":"Crossref","is-referenced-by-count":24,"title":["Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"26","author":[{"given":"Zejun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, First Affiliated Hospital of Kunming Medical University , Kunming , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, First Affiliated Hospital of Kunming Medical University , Kunming , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixue","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"He","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieqiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha, Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"2023062314550616300_CIT0001","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neubiorev.2021.09.020","article-title":"Trace amine-associated receptor 1 (TAAR1): potential application in mood disorders: a systematic review","volume":"131","author":"Alnefeesi","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"2023062314550616300_CIT0002","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0003","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jad.2022.05.098","article-title":"Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness","volume":"311","author":"Baldwin","year":"2022","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0004","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"2023062314550616300_CIT0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jad.2017.12.056","article-title":"The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study","volume":"229","author":"Baune","year":"2018","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0006","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fpsyt.2019.00771","article-title":"Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research","volume":"10","author":"Bennabi","year":"2019","journal-title":"Front Psychiatry"},{"key":"2023062314550616300_CIT0007","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jcpt.13177","article-title":"Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: a double-blind randomized trial","volume":"45","author":"Borhannejad","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2023062314550616300_CIT0008","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2174\/1871527313666141130203823","article-title":"Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review","volume":"13","author":"Bortolato","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2023062314550616300_CIT0009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/03007995.2022.2031146","article-title":"A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder","volume":"38","author":"Bose","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"2023062314550616300_CIT0010","doi-asserted-by":"crossref","first-page":"13070","DOI":"10.3390\/ijms222313070","article-title":"Augmentative pharmacological strategies in treatment-resistant major depression: a comprehensive review","volume":"22","author":"Caldiroli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023062314550616300_CIT0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/24750573.2018.1484013","article-title":"Serious dermatological adverse effects of vortioxetine: two cases.","volume":"28","author":"Cetin","year":"2018","journal-title":"Psychiatr Clin Psychopharmacol"},{"key":"2023062314550616300_CIT0012","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1080\/03007995.2018.1477746","article-title":"Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA)","volume":"34","author":"Chin","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2023062314550616300_CIT0013","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1017\/S1092852919000786","article-title":"Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study","volume":"24","author":"Chokka","year":"2019","journal-title":"CNS Spectr"},{"key":"2023062314550616300_CIT0014","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jad.2019.11.074","article-title":"Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma","volume":"263","author":"Christensen","year":"2020","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0015","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/02698811221090627","article-title":"Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the RECONNECT study","volume":"36","author":"Christensen","year":"2022","journal-title":"J Psychopharmacol"},{"key":"2023062314550616300_CIT0016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/S1092852921000936","article-title":"Vortioxetine 20 mg\/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment","volume":"28","author":"Christensen","year":"2023","journal-title":"CNS Spectr"},{"key":"2023062314550616300_CIT0017","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"2023062314550616300_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ebmental-2019-300080","article-title":"Providing the most appropriate care to our individual patients","volume":"22","author":"Cipriani","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2023062314550616300_CIT0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1176\/appi.ajp.2013.13030325","article-title":"Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses","volume":"171","author":"Cuijpers","year":"2014","journal-title":"Am J Psychiatry"},{"key":"2023062314550616300_CIT0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/wps.20701","article-title":"A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression","volume":"19","author":"Cuijpers","year":"2020","journal-title":"World Psychiatry"},{"key":"2023062314550616300_CIT0021","first-page":"192","article-title":"Treatment effects of vortioxetine on cognitive functions in mild Alzheimer\u2019s disease patients with depressive symptoms: a 12 month, open-label, observational study","volume":"6","author":"Cumbo","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"2023062314550616300_CIT0022","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2023062314550616300_CIT0023","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/14656566.2021.1880567","article-title":"Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?","volume":"22","author":"Danielak","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2023062314550616300_CIT0024","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1590\/1516-4446-2019-0690","article-title":"Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a \u201creal-world\u201d chart review study","volume":"42","author":"De Berardis","year":"2020","journal-title":"Braz J Psychiatry"},{"key":"2023062314550616300_CIT0025","doi-asserted-by":"crossref","first-page":"e2750","DOI":"10.1002\/hup.2750","article-title":"Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: a naturalistic study","volume":"35","author":"De Carlo","year":"2020","journal-title":"Hum Psychopharmacol"},{"key":"2023062314550616300_CIT0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S109285292000173X","article-title":"Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis","volume":"27","author":"Di Nicola","year":"2022","journal-title":"CNS Spectr"},{"key":"2023062314550616300_CIT0027","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jaac.2022.01.004","article-title":"Vortioxetine for major depressive disorder in adolescents: 12-week randomized, placebo-controlled, fluoxetine-referenced, fixed-dose study","volume":"61","author":"Findling","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2023062314550616300_CIT0028","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","journal-title":"Lancet"},{"key":"2023062314550616300_CIT0029","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2023062314550616300_CIT0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","article-title":"Vortioxetine: a novel antidepressant for the treatment of major depressive disorder","volume":"14","author":"Gonda","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"2023062314550616300_CIT0031","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5455\/PBS.20210406034449","article-title":"Skin side effects due to vortioxetine case series.","volume":"11","author":"Gunes","year":"2021","journal-title":"Psychiatry Behav Sci"},{"key":"2023062314550616300_CIT0032","doi-asserted-by":"crossref","first-page":"pyw054","DOI":"10.1093\/ijnp\/pyw054","article-title":"Which cognitive domains are improved by treatment with vortioxetine?","volume":"19","author":"Harrison","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023062314550616300_CIT0033","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)02141-3","article-title":"Time for united action on depression: a Lancet-World Psychiatric Association Commission","volume":"399","author":"Herrman","year":"2022","journal-title":"Lancet"},{"key":"2023062314550616300_CIT0034","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ijnp\/pyac054","article-title":"Effect of vortioxetine on cognitive impairment in patients with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Huang","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023062314550616300_CIT0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/pcn.12623","article-title":"Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial","volume":"72","author":"Inoue","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"2023062314550616300_CIT0036","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/pcn.12956","article-title":"Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder","volume":"74","author":"Inoue","year":"2020","journal-title":"Psychiatry Clin Neurosci"},{"key":"2023062314550616300_CIT0037","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1747-5341-3-14","article-title":"Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?","volume":"3","author":"Ioannidis","year":"2008","journal-title":"Philos Ethics Humanit Med"},{"key":"2023062314550616300_CIT0038","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/WNF.0000000000000490","article-title":"Vortioxetine-induced amenorrhea: a case report","volume":"45","author":"Isik","year":"2022","journal-title":"Clin Neuropharmacol"},{"key":"2023062314550616300_CIT0039","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.euroneuro.2013.10.011","article-title":"Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation","volume":"24","author":"Jensen","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023062314550616300_CIT0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bcp.13772","article-title":"Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis","volume":"85","author":"Liguori","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2023062314550616300_CIT0041","author":"Lundbeck","year":"2018"},{"key":"2023062314550616300_CIT0042","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/npp.2015.52","article-title":"A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder","volume":"40","author":"Mahableshwarkar","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"2023062314550616300_CIT0043","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"2023062314550616300_CIT0044","doi-asserted-by":"crossref","first-page":"824831","DOI":"10.3389\/fpsyt.2022.824831","article-title":"Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study","volume":"13","author":"Mattingly","year":"2022","journal-title":"Front Psychiatry"},{"key":"2023062314550616300_CIT0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1037\/a0017336","article-title":"Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis","volume":"24","author":"McClintock","year":"2010","journal-title":"Neuropsychology"},{"key":"2023062314550616300_CIT0046","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0b013e31820ebd2c","article-title":"Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication","volume":"31","author":"McClintock","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"2023062314550616300_CIT0047","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12888-021-03608-1","article-title":"Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study","volume":"21","author":"McCue","year":"2021","journal-title":"BMC Psychiatry"},{"key":"2023062314550616300_CIT0048","doi-asserted-by":"crossref","first-page":"22","DOI":"10.63050\/jpps.18.01.87","article-title":"REVIDA in Pakistan: impact of vortioxetine on severity, cognitive dysfunctions, and functionality in patients with major depression.","volume":"18","author":"Minhas","year":"2021","journal-title":"J Pakistan Psychiatric Soc"},{"key":"2023062314550616300_CIT0049","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","article-title":"Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder","volume":"340","author":"Mork","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2023062314550616300_CIT0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"2023062314550616300_CIT0051","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pcn.12565","article-title":"Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg\/day vortioxetine in adults with major depressive disorder","volume":"72","author":"Nishimura","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"2023062314550616300_CIT0052","first-page":"87","article-title":"A serious dermatological side effect due to vortioxetine: a case report.","volume":"33","author":"Okumus","year":"2020","journal-title":"Dusunen Adam"},{"key":"2023062314550616300_CIT0053","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1515\/tjb-2018-0106","article-title":"Galactorrhea and hyperprolactinemia during vortioxetine use: case report.","volume":"44","author":"Ozkan","year":"2019","journal-title":"Turkish J Biochem"},{"key":"2023062314550616300_CIT0054","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023062314550616300_CIT0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12888-022-04109-5","article-title":"Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects","volume":"22","author":"Papalexi","year":"2022","journal-title":"BMC Psychiatry"},{"key":"2023062314550616300_CIT0056","doi-asserted-by":"crossref","first-page":"pyv082","DOI":"10.1093\/ijnp\/pyv082","article-title":"The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials","volume":"19","author":"Rosenblat","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023062314550616300_CIT0057","doi-asserted-by":"crossref","first-page":"635502","DOI":"10.3389\/fpsyt.2021.635502","article-title":"Naturalistic and uncontrolled pilot study on the efficacy of vortioxetine in binge eating disorder with comorbid depression","volume":"12","author":"Segura-Garcia","year":"2021","journal-title":"Front Psychiatry"},{"key":"2023062314550616300_CIT0058","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.12669\/pjms.38.5.5230","article-title":"Clinical efficacy of vortioxetine and escitalopram in the treatment of depression","volume":"38","author":"Shao","year":"2022","journal-title":"Pak J Med Sci"},{"key":"2023062314550616300_CIT0059","doi-asserted-by":"crossref","first-page":"198","DOI":"10.24869\/psyd.2021.198","article-title":"Vortioxetine-induced hypomania: a case report","volume":"33","author":"Songur","year":"2021","journal-title":"Psychiatr Danub"},{"key":"2023062314550616300_CIT0060","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023062314550616300_CIT0061","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2022.02.002","article-title":"Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: the RESET study","volume":"303","author":"Thase","year":"2022","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0062","doi-asserted-by":"crossref","first-page":"394","DOI":"10.9758\/cpn.2022.20.2.394","article-title":"Vortioxetine induced hypomania: a case presentation and review of the literature","volume":"20","author":"Tunc","year":"2022","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2023062314550616300_CIT0063","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/1570159X18666200818195720","article-title":"Risks associated with vortioxetine in the established therapeutic indication","volume":"19","author":"Verma","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"2023062314550616300_CIT0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2017.11.056","article-title":"Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis","volume":"228","author":"Wagner","year":"2018","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0065","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2147\/NDT.S358253","article-title":"Effectiveness and safety of vortioxetine for major depressive disorder in real-world clinical practice: results from the single-arm RELIEVE China study","volume":"18","author":"Wang","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2023062314550616300_CIT0066","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jad.2012.03.034","article-title":"Cognitive functioning in euthymic recurrently depressed patients: relationship with future relapses and prior course of disease","volume":"141","author":"Wekking","year":"2012","journal-title":"J Affect Disord"},{"key":"2023062314550616300_CIT0067","author":"World Health Organization","year":"2021"},{"key":"2023062314550616300_CIT0068","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1080\/03007995.2021.1980869","article-title":"A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA)","volume":"37","author":"Yang","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2023062314550616300_CIT0069","first-page":"164","article-title":"Treatment of depression with vortioxetine in a patient with comorbid major depressive disorder and restless legs syndrome: a case report","volume":"59","author":"Yilbas","year":"2022","journal-title":"Noro Psikiyatr Ars"},{"key":"2023062314550616300_CIT0070","first-page":"86","article-title":"Skin reaction associated with vortioxetine: purpuric rash.","volume":"30","author":"Yildiz","year":"2020","journal-title":"Psychiatr Clin Psychopharmacol"},{"key":"2023062314550616300_CIT0071","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12991-021-00340-8","article-title":"Major depression with musical obsession treated with vortioxetine: a case report","volume":"20","author":"Yoshimura","year":"2021","journal-title":"Ann Gen Psychiatry"},{"key":"2023062314550616300_CIT0072","doi-asserted-by":"crossref","first-page":"922648","DOI":"10.3389\/fpsyt.2022.922648","article-title":"Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Psychiatry"},{"key":"2023062314550616300_CIT0073","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.4314\/ahs.v19i1.48","article-title":"The efficacy and safety of 10 mg\/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis","volume":"19","author":"Zheng","year":"2019","journal-title":"Afr Health Sci"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyad018\/50457131\/pyad018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/6\/373\/50685253\/pyad018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/6\/373\/50685253\/pyad018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T10:16:56Z","timestamp":1729333016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/26\/6\/373\/7146181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,4,27]]},"published-print":{"date-parts":[[2023,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyad018","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,4,27]]}}}